(Q28300187)

https://api.crossref.org/works/10.1517/14656566.8.7.923

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.8.7.923

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.8.7.923

CCR5 deficiency increases risk of symptomatic West Nile virus infection

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.8.7.923

Assessing chemokine co-receptor usage in HIV

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.8.7.923

21 April 2017

Chemokines and disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The many roles of chemokines and chemokine receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Enfuvirtide: the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

A new classification for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Oral CCR5 inhibitors: will they make it through?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The HIV coreceptor switch: a population dynamical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Biology of CCR5 and its role in HIV infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

A genetic approach to inactivating chemokine receptors using a modified viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

The role of chemokine receptors in primary, effector, and memory immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923

Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.923